SARS-CoV-2 is the pathogen responsible for the COVID-19 pandemic. The SARS-CoV-2 papain-like cysteine protease (PLpro) has been implicated in playing important roles in virus maturation, dysregulation of host inflammation, and antiviral immune responses. The multiple functions of PLpro render it a promising drug target. Therefore, we screened a library of approved drugs and also examined available inhibitors against PLpro. Inhibitor GRL0617 showed a promising in vitro IC50 of 2.1 μM and an effective antiviral inhibition in cell-based assays. The co-crystal structure of SARS-CoV-2 PLproC111S in complex with GRL0617 indicates that GRL0617 is a non-covalent inhibitor and it resides in the ubiquitin-specific proteases (USP) domain of PLpro. NMR data indicate that GRL0617 blocks the binding of ISG15 C-terminus to PLpro. Using truncated ISG15 mutants, we show that the C-terminus of ISG15 plays a dominant role in binding PLpro. Structural analysis reveals that the ISG15 C-terminus binding pocket in PLpro contributes a disproportionately large portion of binding energy, thus this pocket is a hot spot for antiviral drug discovery targeting PLpro.

No abstract

No abstract

Distant supervision for neural relation extraction is an efficient approach to extracting massive relations with reference to plain texts. However, the existing neural methods fail to capture the critical words in sentence encoding and meanwhile lack useful sentence information for some positive training instances. To address the above issues, we propose a novel neural relation extraction model. First, we develop a word-level attention mechanism to distinguish the importance of each individual word in a sentence, increasing the attention weights for those critical words. Second, we investigate the semantic information from word embeddings of target entities, which can be developed as a supplementary feature for the extractor. Experimental results show that our model outperforms previous state-of-the-art baselines.

The pseudokinase RNase L is a functional ribonuclease and plays important roles in human innate immunity. The ribonuclease activity of RNase L can be regulated by the kinase inhibitor sunitinib. The combined use of oncolytic virus and sunitinib has been shown to exert synergistic effects in anticancer therapy. In this study, we aimed to uncover the mechanism of action through which sunitinib inhibits RNase L. We solved the crystal structures of RNase L in complex with sunitinib and its analogs toceranib and SU11652. Our results showed that sunitinib bound to the ATP-binding pocket of RNase L. Unexpectedly, the αA helix linking the ankyrin repeat-domain and the pseudokinase domain affected the binding mode of sunitinib and resulted in an usual flipped orientation relative to other strucutres in PDB. Molecular dynamics simulations and dynamic light scattering results support that the binding of sunitinib in the pseudokinase domain destabilized the dimer conformation of RNase L and allosterically inhibited its ribonuclease activity. Our study suggested that dimer destabilization could be an effective strategy for the discovery of RNase L inhibitors and that targeting the ATP-binding pocket in the pseudokinase domain of RNase L was an efficient approach for modulating its ribonuclease activity.